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ABSTRACT
Linezolid is not yet recognised as a standard
therapy for infective endocarditis. This report
describes nine patients with endocarditis treated
with linezolid and 33 similar cases from the
medical literature. The majority of cases in-
volved multiresistant strains, and the reasons
for administering linezolid were refractory
disease (60%), intolerance (28%), sequential
therapy (12%) and a resistant pathogen (1%).
Linezolid was administered for a mean of
37 days, with a successful outcome in 79% of
cases. Reversible adverse effects were described
in ten cases. The mean follow-up period was
8.5 months. Further data from randomised con-
trolled clinical trials are needed to determine
the efﬁcacy and safety of linezolid for treating
endocarditis.
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Linezolid (LNZ) has excellent in-vitro activity
against Gram-positive bacteria that cause endo-
carditis. However, linezolid is not yet recognised
as a standard therapy for this condition because
of concerns regarding its bacteriostatic activity
and long-term toxicity. This report describes nine
patients with endocarditis who were treated with
linezolid and summarises another 33 cases report-
ed previously in the literature.
LNZ was used to treat nine (8.5%) of 106
patients with endocarditis during a 13-month
period because of refractory disease (n = 2) or
intolerance to other drugs (n = 4), or for out-
patient oral consolidation treatment (n = 3). The
clinical features of these nine patients are sum-
marised in Table 1. The mean age was 69 (range
57–82) years, and six were male. Underlying
conditions included bone marrow and kidney
transplantation (n = 2) and previous heart disease
(n = 6). Aetiological agents were Staphylococcus
aureus (n = 6), coagulase-negative staphylococci
(n = 1), Corynebacterium striatum (n = 1) and Strep-
tococcus mutans (n = 1). Eight cases involved the
left side of the heart, with ﬁve cases occurring in
prosthetic valves. Four patients required surgery.
The median length of previous in-hospital ther-
apy with other standard drugs was 22 (range
14–28) days, and the mean duration of LNZ
therapy was 20 (range 14–28) days. All nine
patients were cured, with no adverse effects or
relapses.
At present, linezolid is not a standard therapy
for endocarditis, although guidelines published
recently by the American Heart Association con-
sider it to be a reasonable alternative for cases
of endocarditis caused by methicillin-resistant
S. aureus (MRSA) or multiresistant enterococci.
Experience with linezolid for the treatment of
endocarditis is limited, and no comparative stud-
ies are available. Experimental models show
discordant results, but 33 other cases of endocar-
ditis treated with linezolid have been described
previously in the literature [1–23]. The most
important features of all 42 cases are summa-
rised in Table 2. The mean age was 63 (range
1–82) years, and 63% of patients were male.
All patients except one [11] had a severe under-
lying condition, with the most common being
previous heart disease (62%) and renal insufﬁ-
ciency (26%).
Endocarditis was left-sided in 76% of cases and
occurred on a prosthetic valve in 33% of cases. T
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Multiresistant bacteria predominated, including
MRSA (n = 11), S. aureus with reduced vancomy-
cin susceptibility (n = 11), vancomycin-resistant
enterococci (n = 7), and high-level gentamicin-
resistant Enterococcus spp. (n = 2). The most
important reason for administering linezolid
was previous failure of a more conventional
antimicrobial regimen (60%). Thirty-eight pa-
tients had received previous therapy for a mean
of 30 (range 4–90) days. Previous therapy was
signiﬁcantly longer in refractory patients (38 days
vs. 21 days; p 0.03). Nevertheless, 22 refractory
patients were persistently bacteraemic when
linezolid therapy was commenced, and two
patients experienced signiﬁcant clinical deteri-
oration (a CNS event and a constant fever with
vegetation enlargement, respectively). Linezolid
was administered for a mean of 37 days, but
longer for refractory patients (46 vs. 24 days;
p <0.01). The route of administration was speci-
ﬁed for 32 patients, with 50% receiving oral
therapy (Table 2). The outcome was signiﬁcantly
better in this group (a cure rate of 95% vs. 64%),
probably because intravenous therapy was re-
served for the most severely-ill patients.
Surgery was performed on 12 patients, and
other drugs were given with linezolid to 11
patients. Adverse effects were uncommon, even
with patients who received prolonged therapy
[10,12], but nine patients had thrombocytopenia
and one had minor diarrhoea. None of the
patients experienced severe or permanent side-
effects, and no relationship was found between
toxicity and duration of linezolid therapy, or the
presence of chronic renal failure, or previous use
of vancomycin. However, the possibility of per-
manent neurological toxicity is a signiﬁcant con-
cern; thus, when therapy is for longer than
2 weeks, the possibility of reversible thrombocy-
topenia should be investigated on a weekly basis,
especially for patients receiving haemodialysis.
The use of linezolid for >28 days is not recom-
mended.
The mean follow-up period was 8.5 months,
and the outcome was considered to be successful
for 33 (79%) patients. A favourable outcome was
less common for patients with cancer (50% vs.
85%, p 0.02), but no difference in outcome was
observed with respect to aetiology, the indication
for linezolid, or prosthetic valve endocarditis.
Three of the patients classiﬁed as clinical failures
died while receiving therapy, but without signs of
endocarditis and with negative cultures. Related
death occurred with six (14%) patients, and was
more common in patients with diabetes mellitus
(43% vs. 9%; p 0.01) and cancer (37.5% vs. 9%,
p 0.03), and those who received linezolid follow-
ing previous treatment failure (20% vs. 6%;
p 0.1).
The response was satisfactory for eight of 11
patients with MRSA (two of whom were also
infected with Enterococcus spp.), and for seven of
11 patients with endocarditis caused by S. aureus
with reduced susceptibility to vancomycin
[7,12–14]. Endocarditis caused by vancomycin-
resistant enterococci also showed a high response
rate to linezolid, with four of ﬁve cases cured
[3–6]. The patient who died had negative cultures
1 week after starting therapy [15]. This patient
was receiving haemodialysis, which has been
Table 2. Summary of 42 cases of infective endocarditis
treated with linezolid
Male (%) 26 ⁄ 41 (63%)
Mean age ⁄ years (range) 63 (1–82)
Underlying conditions, n (%) 41 (98%)
Previous heart disease 26 (62%)
Renal insufﬁciency 11 (26%)
Cancer 8 (19%)
Diabetes mellitus 7 (17%)
Transplantation 4 (9.5%)
Endocarditis characteristics, n (%)
Left-sided 32 (76%)
Prosthetic valve 14 (33%)
Multiple valve involvement 8 (9%)
Septic metastasesa 6
Aetiology, n (%)b
Staphylococcus 31 (74%)
Methicillin-resistant S. aureus (MRSA) 11
S. aureus with reduced susceptibility to vancomycin 11
Methicillin-susceptible S. aureus 4
Coagulase-negative Staphylococcus 5
Enterococcus spp. 10 (24%)
Vancomycin-resistant Enterococcus 7
High-level gentamicin-resistant Enterococcus 2
Others (Streptococcus mitis and Corynebacterium striatum) 2
Reasons for administering linezolid, n (%)
Failure of previous treatment 25 (60%)
Intolerance 11 (28%),
Sequential therapy 5 (12%)
Initial treatment for multiresistant pathogen 1
Therapy of the endocarditis
Mean duration of previous therapy 30 (4–90) days
Mean duration of linezolid administration 37 (7–156) days
Simultaneous drugsc, n 11
Surgery, n (%) 12 (29%)
Adverse effects of linezolid therapy, n (%) 10 (24%)
Thrombocytopenia 9
Diarrhoea 1
Outcome
Mean follow-up period 8.5 months
Cure, n (%) 33 (79%)
Non-related death, n (%)d 3
Related death, n (%) 6 (14%)
aBrain, aortic root, spleen, kidney, vertebra, epidural and psoas abscess.
bTwo patients had endocarditis caused simultaneously by MRSA and Enterococcus
spp.
cAminoglycosides (n = 5), rifampicin (n = 5), fusidic acid (n = 3), and vancomycin
(n = 3).
dThree patients were classiﬁed as clinical failures as they died during therapy, but
without signs of endocarditis and with negative cultures.
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associated previously with lower plasma levels of
linezolid. It has been suggested that higher doses
of linezolid may be necessary to achieve cure in
some refractory cases. Moreover, an animal
model of endocarditis in rabbits showed that
the efﬁcacy of linezolid was related to trough
levels in plasma, and that high levels of linezolid
are required to cure endocarditis. It is not clear
which factors may be associated with unexpect-
edly low levels of linezolid, or whether a speciﬁc
group of patients is especially predisposed to low
levels.
A prospective, blind, comparative study would
be necessary to clarify aspects such as the efﬁcacy
of linezolid for treatment of this condition and
to exclude possible under-reporting of side-
effects. The possibility of a reporting bias cannot
be excluded, i.e., cases with a more favourable
outcome have been reported. Finally, it can be
argued that cure could be attributed to the use of
previous or concomitant antibiotics prescribed to
the patients. However, this seems unlikely, as
most of the patients had refractory disease with
persistent bacteraemia when linezolid therapy
was commenced, despite prolonged previous
standard treatment. Nevertheless, this possi-
bility cannot be excluded in patients for whom
linezolid was used as consolidation therapy,
particularly as the duration of therapy for endo-
carditis is not clearly established. Longer follow-
up periods may be needed to exclude a higher
rate of relapse.
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